Fortress Biotech (FBIO) vs Medicinova (MNOV)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Medicinova (MNOV) has outperformed Fortress Biotech (FBIO) over the past year, losing 8.4% versus a loss of 26.6%. Over five years, MNOV leads with a -59.3% price change compared with -95.5% for FBIO. Medicinova is the larger company by market cap ($67.1 million vs $64.1 million), about 1.0 times the size.
Fortress Biotech converts more of its revenue into profit, with a net margin of 10.8% versus -2928.8%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | FBIO | MNOV |
|---|---|---|
| Share price | $1.90 | $1.31 |
| Market cap | $64.11M | $67.11M |
| 1-day change | +7.34% | +3.15% |
| YTD return | -48.09% | 0.00% |
| 1-year return | -26.64% | -8.39% |
| 5-year return | -95.52% | -59.32% |
| P/E ratio (TTM) | 0.83 | — |
| EPS (TTM) | $2.30 | $-0.21 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $63.26M | $409.66K |
| Revenue growth (YoY) | +9.69% | — |
| Net income (latest FY) | $6.82M | $-12.00M |
| Gross margin | 66.92% | — |
| Operating margin | -111.00% | -3242.47% |
| Net margin | 10.77% | -2928.78% |
| 52-week high | $4.53 | $3.90 |
| 52-week low | $1.64 | $1.22 |
| Distance from 52-week high | -58.06% | -66.41% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +163.16% | +529.77% |
| Average volume | 281.49K | 334.96K |
| Shares outstanding | 33.74M | 51.23M |
| Employees | 78 | 6 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MNOV has outperformed FBIO by 18.2 percentage points over the past year.
- Fortress Biotech is more profitable, keeping 10.8 cents of every revenue dollar as net income versus -2928.8 cents for Medicinova.
About Fortress Biotech
FBIO stock →Fortress Biotech, Inc., together with its subsidiaries, operates as a biopharmaceutical company in the United States and internationally. The company offers Emrosi, a minocycline hydrochloride extended-release capsule for the treatment of rosacea; Qbrexza a medicated cloth towelette for the treatment of axillary hyperhidrosis; Accutane, an oral isotretinoin drug for the treatment of severe recalcitrant nodular acne; Amzeeq, a minocycline topical foam for the treatment of lesions of non-nodular moderate to severe acne vulgaris; Zilxi, a minocycline topical foam for the treatment of lesions of rosacea; Exelderm, an antifungal cream for topical use; Targadox, an oral doxycycline drug for the therapy of severe acne; Luxamend, a water-based emulsion for the treatment of superficial wounds, minor cuts or scrapes, dermal ulcers, donor sites, first and second-degree burns, and radiation dermatitis; and UNLOXCYT, a death-ligand 1 blocking antibody for the treatment of metastatic cutaneous squamous cell carcinoma.
Health Care · Biotechnology: Pharmaceutical Preparations · 78 employees
About Medicinova
MNOV stock →MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It develops MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent in Phase 2 clinical trial for treating neurological and other disorders, such as progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, and glioblastoma, as well as prevention of acute respiratory distress syndrome.
Health Care · Biotechnology: Pharmaceutical Preparations · 6 employees
FBIO vs MNOV FAQ
Which is bigger, Fortress Biotech or Medicinova?
Medicinova (MNOV) is larger, with a market capitalization of $67.11M compared with $64.11M for Fortress Biotech (FBIO).
Which stock has performed better over the past year, FBIO or MNOV?
MNOV returned -8.39% over the past 12 months, compared with -26.64% for FBIO (price return, excluding dividends). Past performance does not predict future results.
Are Fortress Biotech and Medicinova in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.